Zorac en es it fr

Zorac Brand names, Zorac Analogs

Zorac Brand Names Mixture

  • No information avaliable

Zorac Chemical_Formula


Zorac RX_link


Zorac fda sheet

Zorac FDA

Zorac msds (material safety sheet)

Zorac MSDS

Zorac Synthesis Reference

No information avaliable

Zorac Molecular Weight

263.786 g/mol

Zorac Melting Point

No information avaliable

Zorac H2O Solubility

Freely soluble

Zorac State


Zorac LogP


Zorac Dosage Forms

Tablets (for oral administration, containing 250 mg of ticlopidine hydrochloride)

Zorac Indication

Used to reduce the risk of thrombotic stroke (fatal or nonfatal) in patients who have experienced stroke precursors, and in patients who have had a completed thrombotic stroke.

Zorac Pharmacology

Ticlopidine is a platelet aggregation inhibitor structurally and pharmacologically similar to clopidogrel. When taken orally, ticlopidine causes a time- and dose-dependent inhibition of both platelet aggregation and release of platelet granule constituents, as well as a prolongation of bleeding time. The intact drug has no significant in vitro activity at the concentrations attained in vivo; and, although analysis of urine and plasma indicates at least 20 metabolites, no metabolite which accounts for the activity of ticlopidine has been isolated.

Zorac Absorption

Absorption is greater than 80%. Food increases absorption.

Zorac side effects and Toxicity

Single oral doses of ticlopidine at 1600 mg/kg and 500 mg/kg were lethal to rats and mice, respectively. Symptoms of acute toxicity were GI hemorrhage, convulsions, hypothermia, dyspnea, loss of equilibrium and abnormal gait.

Zorac Patient Information

Zorac Organisms Affected

Humans and other mammals